Rotigaptide (ZP123) significantly reduced the average defibrillation energy required for successful cardioversion (239 J vs 406 J in the 8-min VF group) and improved defibrillation success rates in a canine model of ventricular fibrillation.
RCT (n=56)
Single-blind
Randomly divided
No
Does rotigaptide (ZP123) improve defibrillation success and reduce defibrillation energy in a canine model of prolonged ventricular fibrillation?
Rotigaptide (ZP123) reduces the defibrillation energy required for successful cardioversion in a canine model of prolonged ventricular fibrillation by preventing connexin43 remodeling.
Absolute Event Rate: 239% vs 406%
p-value: p=<0.05
The present study investigated the effects of rotigaptide (ZP123) on the expression, distribution and phosphorylation of connexin43 (Cx43) in myocardial cell membranes in cardioversion of ventricular fibrillation (VF). A model of prolonged VF (8, 12 and 30 min) was established in mongrel dogs (n=8/group), following treatment with ZP123 or normal saline (NS control). A sham control was included. Cardiopulmonary resuscitation was begun at the start of VF followed by defibrillation. Animals received a maximum of three defibrillations of increasing energy (70, 100 and 150 J biphasic shock) as required. The average defibrillation energy, defibrillation success rate, return of spontaneous circulation and survival rate were recorded. Cx43 and phosphorylated (p-)Cx43 expression in cardiomyocyte membranes was detected by western blot and immunofluorescence analyses. Compared with the NS-treated control groups, the success defibrillation rate in the 8-min and 12-min ZP123 groups was significantly higher (P<0.05), while the average defibrillation energy was significantly lower (P<0.05). Cx43 expression in the VF groups was significantly lower than that in the sham control group (P<0.05). Cx43 expression was higher in the 12-min and 30-min ZP123 groups than that in the NS control group (P<0.05), while p-Cx43 expression decreased, although the levels were significantly higher than those in the control groups (P<0.05). Cx43 expression was positively correlated with the defibrillation success rate (r=0.91; P<0.01) and negatively with the mean defibrillation energy (r=-0.854; P<0.01), while p-Cx43 expression was positively correlated with the success rate of the previous three defibrillations (r=0.926; P<0.01).In conclusion, ZP123 reduced Cx43 remodeling through regulating the expression, distribution and phosphorylation of Cx43, thereby reducing the defibrillation energy required for successful cardioversion.
Su et al. (2015) conducted an RCT in Ventricular fibrillation (n=56). Rotigaptide (ZP123) vs. Normal saline was evaluated on Average defibrillation energy in 8-min ventricular fibrillation model (Joules) (p=<0.05). Rotigaptide (ZP123) significantly reduced the average defibrillation energy required for successful cardioversion (239 J vs 406 J in the 8-min VF group) and improved defibrillation success rates in a canine model of ventricular fibrillation.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: